{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T17:13:49Z","timestamp":1788542029709,"version":"build-2803163510"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T00:00:00Z","timestamp":1785110400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Pharmacokinet"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1007\/s40262-026-01672-y","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T17:24:00Z","timestamp":1785173040000},"page":"1389-1403","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Population Pharmacokinetics of Bosutinib in Children with Philadelphia Chromosome-Positive Chronic Myelogenous Leukemia Based on a Phase I Dose-Finding Trial (ITCC-054\/COG AAML1921) and Pediatric Recommended Phase II Dosage Evaluation"],"prefix":"10.1007","volume":"65","author":[{"given":"Jen-Hao","family":"Wu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francisco","family":"Bautista","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica","family":"Brivio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marieke","family":"Willemse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karey","family":"Kowalski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Jermain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"May","family":"Garrett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Bukowinski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carmelo","family":"Rizzari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica","family":"Pollard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Murillo-Sanju\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Kutny","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Zarnegar-Lumley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Redell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacy","family":"Cooper","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yves","family":"Bertrand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Petit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Krystal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Markus","family":"Metzler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Lancaster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Pierre","family":"Bourquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jayashree","family":"Motwani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Inge M.","family":"van der Sluis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Franco","family":"Locatelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael E.","family":"Roth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuko","family":"Hijiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6892-8268","authenticated-orcid":false,"given":"C. Michel","family":"Zwaan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alwin D. R.","family":"Huitema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,7,27]]},"reference":[{"key":"1672_CR1","doi-asserted-by":"publisher","first-page":"11314","DOI":"10.1158\/0008-5472.CAN-06-1199","volume":"66","author":"M Puttini","year":"2006","unstructured":"Puttini M, Coluccia AML, Boschelli F, Cleris L, Marchesi E, Donella-Deana A, et al. In vitro and in vivo activity of SKI-606, a novel Src-Abl inhibitor, against imatinib-resistant Bcr-Abl+ neoplastic cells. Cancer Res. 2006;66:11314\u201322. https:\/\/doi.org\/10.1158\/0008-5472.CAN-06-1199.","journal-title":"Cancer Res"},{"key":"1672_CR2","first-page":"375","volume":"63","author":"JM Golas","year":"2003","unstructured":"Golas JM, Arndt K, Etienne C, Lucas J, Nardin D, Gibbons J, et al. SKI-606, a 4-anilino-3-quinolinecarbonitrile dual inhibitor of Src and Abl kinases, is a potent antiproliferative agent against chronic myelogenous leukemia cells in culture and causes regression of K562 xenografts in nude mice. Cancer Res. 2003;63:375\u201381.","journal-title":"Cancer Res"},{"key":"1672_CR3","unstructured":"European Medicines Agency. Bosulif; INN-bosutinib [Product Information]. 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/bosulif-epar-product-information_en.pdf."},{"key":"1672_CR4","unstructured":"FDA. BOSULIF\u00ae (bosutinib) tablets and capsules, for oral use [prescribing information]. 2024. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/203341s026lbl.pdf."},{"key":"1672_CR5","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1200\/JCO.23.00897","volume":"42","author":"E Brivio","year":"2024","unstructured":"Brivio E, Pennesi E, Willemse ME, Huitema ADR, Jiang Y, van Tinteren HDR, et al. Bosutinib in resistant and intolerant pediatric patients with chronic phase chronic myeloid leukemia: results from the phase I part of study ITCC054\/COG AAML1921. J Clin Oncol. 2024;42:821\u201331. https:\/\/doi.org\/10.1200\/JCO.23.00897.","journal-title":"J Clin Oncol"},{"key":"1672_CR6","unstructured":"European Medicines Agency. Bosulif - opinion on variation to marketing authorisation | European Medicines Agency (EMA) 2025. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/variation\/bosulif."},{"key":"1672_CR7","doi-asserted-by":"publisher","first-page":"17981","DOI":"10.1002\/cam4.6439","volume":"12","author":"M Garrett","year":"2023","unstructured":"Garrett M, Knight B, Cortes JE, Deininger MW. Population modeling of bosutinib exposure\u2010response in patients with newly diagnosed chronic phase chronic myeloid leukemia. Cancer Med. 2023;12:17981\u201392. https:\/\/doi.org\/10.1002\/cam4.6439.","journal-title":"Cancer Med"},{"key":"1672_CR8","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1016\/j.ejca.2017.07.050","volume":"85","author":"JM Janssen","year":"2017","unstructured":"Janssen JM, Zwaan CM, Schellens JHM, Beijnen JH, Huitema ADR. Clinical trial simulations in paediatric oncology: a feasibility study from the Innovative Therapies for Children with Cancer Consortium. Eur J Cancer. 2017;85:78\u201385. https:\/\/doi.org\/10.1016\/j.ejca.2017.07.050.","journal-title":"Eur J Cancer"},{"key":"1672_CR9","doi-asserted-by":"publisher","unstructured":"Gabrielsson J, Weiner D. Non-compartmental analysis, 2012, p. 377\u201389. https:\/\/doi.org\/10.1007\/978-1-62703-050-2_16.","DOI":"10.1007\/978-1-62703-050-2_16"},{"key":"1672_CR10","doi-asserted-by":"publisher","first-page":"1983","DOI":"10.2174\/138920111798808400","volume":"12","author":"K Patel","year":"2011","unstructured":"Patel K, Kirkpatrick MJC. Pharmacokinetic concepts revisited - basic and applied. Curr Pharm Biotechnol. 2011;12:1983\u201390. https:\/\/doi.org\/10.2174\/138920111798808400.","journal-title":"Curr Pharm Biotechnol"},{"key":"1672_CR11","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1002\/9783527609628.ch7","volume-title":"Pharmacokinetics and pharmacodynamics of biotech drugs","author":"AB Straughn","year":"2006","unstructured":"Straughn AB. Limitations of noncompartmental pharmacokinetic analysis of biotech drugs. In: Pharmacokinetics and pharmacodynamics of biotech drugs. Wiley; 2006. p. 181\u20138. https:\/\/doi.org\/10.1002\/9783527609628.ch7."},{"key":"1672_CR12","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1002\/psp4.12404","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part I: description of commands and options, with simple examples of population analysis. CPT Pharmacomet Syst Pharmacol. 2019;8:525\u201337. https:\/\/doi.org\/10.1002\/psp4.12404.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1672_CR13","doi-asserted-by":"publisher","first-page":"538","DOI":"10.1002\/psp4.12422","volume":"8","author":"RJ Bauer","year":"2019","unstructured":"Bauer RJ. NONMEM tutorial part II: estimation methods and advanced examples. CPT Pharmacomet Syst Pharmacol. 2019;8:538\u201356. https:\/\/doi.org\/10.1002\/psp4.12422.","journal-title":"CPT Pharmacomet Syst Pharmacol"},{"key":"1672_CR14","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1023\/A:1022972420004","volume":"29","author":"PO Gisleskog","year":"2002","unstructured":"Gisleskog PO, Karlsson MO, Beal SL. Use of prior information to stabilize a population data analysis. J Pharmacokinet Pharmacodyn. 2002;29:473\u2013505. https:\/\/doi.org\/10.1023\/A:1022972420004.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1672_CR15","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","volume":"47","author":"AH-XP Chan Kwong","year":"2020","unstructured":"Chan Kwong AH-XP, Calvier EAM, Fabre D, Gattacceca F, Khier S. Prior information for population pharmacokinetic and pharmacokinetic\/pharmacodynamic analysis: overview and guidance with a focus on the NONMEM PRIOR subroutine. J Pharmacokinet Pharmacodyn. 2020;47:431\u201346. https:\/\/doi.org\/10.1007\/s10928-020-09695-z.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1672_CR16","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2133\/dmpk.24.25","volume":"24","author":"BJ Anderson","year":"2009","unstructured":"Anderson BJ, Holford NHG. Mechanistic basis of using body size and maturation to predict clearance in humans. Drug Metab Pharmacokinet. 2009;24:25\u201336. https:\/\/doi.org\/10.2133\/dmpk.24.25.","journal-title":"Drug Metab Pharmacokinet"},{"key":"1672_CR17","doi-asserted-by":"publisher","first-page":"2941","DOI":"10.1002\/jps.23574","volume":"102","author":"N Holford","year":"2013","unstructured":"Holford N, Heo Y-A, Anderson B. A pharmacokinetic standard for babies and adults. J Pharm Sci. 2013;102:2941\u201352. https:\/\/doi.org\/10.1002\/jps.23574.","journal-title":"J Pharm Sci"},{"key":"1672_CR18","doi-asserted-by":"publisher","first-page":"143","DOI":"10.1208\/s12248-011-9255-z","volume":"13","author":"M Bergstrand","year":"2011","unstructured":"Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J. 2011;13:143\u201351. https:\/\/doi.org\/10.1208\/s12248-011-9255-z.","journal-title":"AAPS J"},{"key":"1672_CR19","doi-asserted-by":"publisher","first-page":"509","DOI":"10.1007\/s10928-017-9542-0","volume":"44","author":"A-G Dosne","year":"2017","unstructured":"Dosne A-G, Bergstrand M, Karlsson MO. An automated sampling importance resampling procedure for estimating parameter uncertainty. J Pharmacokinet Pharmacodyn. 2017;44:509\u201320. https:\/\/doi.org\/10.1007\/s10928-017-9542-0.","journal-title":"J Pharmacokinet Pharmacodyn"},{"key":"1672_CR20","unstructured":"National Health and Nutrition Examination Survey (NHANES). NHANES Questionnaires, Datasets, and Related Documentation 2024. https:\/\/wwwn.cdc.gov\/nchs\/nhanes\/continuousnhanes\/default.aspx?Cycle=2021-2023."},{"key":"1672_CR21","doi-asserted-by":"publisher","first-page":"85","DOI":"10.1016\/j.cmpb.2003.11.003","volume":"75","author":"L Lindbom","year":"2004","unstructured":"Lindbom L, Ribbing J, Jonsson EN. Perl-speaks-NONMEM (PsN)\u2014a Perl module for NONMEM related programming. Comput Methods Programs Biomed. 2004;75:85\u201394. https:\/\/doi.org\/10.1016\/j.cmpb.2003.11.003.","journal-title":"Comput Methods Programs Biomed"},{"key":"1672_CR22","doi-asserted-by":"publisher","first-page":"72","DOI":"10.1016\/j.cmpb.2010.04.018","volume":"101","author":"RJ Keizer","year":"2011","unstructured":"Keizer RJ, van Benten M, Beijnen JH, Schellens JHM, Huitema ADR. Pira\u00f1a and PCluster: a modeling environment and cluster infrastructure for NONMEM. Comput Methods Programs Biomed. 2011;101:72\u20139. https:\/\/doi.org\/10.1016\/j.cmpb.2010.04.018.","journal-title":"Comput Methods Programs Biomed"},{"key":"1672_CR23","doi-asserted-by":"publisher","first-page":"10017","DOI":"10.1200\/jco.2024.42.16_suppl.10017","volume":"42","author":"C Rigaud","year":"2024","unstructured":"Rigaud C, Schellekens K, Damm-Welk C, Minard-Colin V, Bakker G, Boonstra-Schelfhorst M, et al. Brigatinib monotherapy in children with R\/R ALK + ALCL, IMT, or other solid tumors: results from the BrigaPED (ITCC-098) phase 1 study. J Clin Oncol. 2024;42:10017\u201310017. https:\/\/doi.org\/10.1200\/jco.2024.42.16_suppl.10017.","journal-title":"J Clin Oncol"},{"key":"1672_CR24","doi-asserted-by":"publisher","first-page":"812","DOI":"10.1158\/1078-0432.CCR-19-0090","volume":"26","author":"N Hijiya","year":"2020","unstructured":"Hijiya N, Zwaan CM, Rizzari C, Fo\u00e0 R, Abbink F, Lancaster D, et al. Pharmacokinetics of nilotinib in pediatric patients with philadelphia chromosome-positive chronic myeloid leukemia or acute lymphoblastic leukemia. Clin Cancer Res. 2020;26:812\u201320. https:\/\/doi.org\/10.1158\/1078-0432.CCR-19-0090.","journal-title":"Clin Cancer Res"},{"key":"1672_CR25","doi-asserted-by":"publisher","first-page":"107","DOI":"10.1007\/s40259-013-0082-x","volume":"28","author":"YY Syed","year":"2014","unstructured":"Syed YY, McCormack PL, Plosker GL. Bosutinib: a review of its use in patients with philadelphia chromosome-positive chronic myelogenous leukemia. BioDrugs. 2014;28:107\u201320. https:\/\/doi.org\/10.1007\/s40259-013-0082-x.","journal-title":"BioDrugs"},{"key":"1672_CR26","doi-asserted-by":"publisher","first-page":"390","DOI":"10.1124\/dmd.116.074450","volume":"45","author":"C Ono","year":"2017","unstructured":"Ono C, Hsyu P-H, Abbas R, Loi C-M, Yamazaki S. Application of physiologically based pharmacokinetic modeling to the understanding of bosutinib pharmacokinetics: prediction of drug\u2013drug and drug\u2013disease interactions. Drug Metab Dispos. 2017;45:390\u20138. https:\/\/doi.org\/10.1124\/dmd.116.074450.","journal-title":"Drug Metab Dispos"},{"issue":"3","key":"1672_CR27","doi-asserted-by":"publisher","first-page":"S128","DOI":"10.1067\/mai.2000.109419","volume":"106","author":"GL Kearns","year":"2000","unstructured":"Kearns GL. Impact of developmental pharmacology on pediatric study design: overcoming the challenges. J Allergy Clin Immunol. 2000;106(3):S128. https:\/\/doi.org\/10.1067\/mai.2000.109419.","journal-title":"J Allergy Clin Immunol"},{"key":"1672_CR28","doi-asserted-by":"publisher","first-page":"485","DOI":"10.2165\/00003088-199937060-00004","volume":"37","author":"SN de Wildt","year":"1999","unstructured":"de Wildt SN, Kearns GL, Leeder JS, van den Anker JN. Cytochrome P450 3A: ontogeny and drug disposition. Clin Pharmacokinet. 1999;37:485\u2013505. https:\/\/doi.org\/10.2165\/00003088-199937060-00004.","journal-title":"Clin Pharmacokinet"},{"key":"1672_CR29","doi-asserted-by":"publisher","first-page":"2221","DOI":"10.1007\/s00044-024-03360-7","volume":"33","author":"M Vander Schaaf","year":"2024","unstructured":"Vander Schaaf M, Luth K, Townsend DM, Chessman KH, Mills CM, Garner SS, et al. CYP3A4 drug metabolism considerations in pediatric pharmacotherapy. Med Chem Res. 2024;33:2221\u201335. https:\/\/doi.org\/10.1007\/s00044-024-03360-7.","journal-title":"Med Chem Res"},{"key":"1672_CR30","doi-asserted-by":"publisher","first-page":"333","DOI":"10.1007\/s40262-013-0041-1","volume":"52","author":"I Ince","year":"2013","unstructured":"Ince I, Knibbe CAJ, Danhof M, de Wildt SN. Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations. Clin Pharmacokinet. 2013;52:333\u201345. https:\/\/doi.org\/10.1007\/s40262-013-0041-1.","journal-title":"Clin Pharmacokinet"},{"key":"1672_CR31","doi-asserted-by":"publisher","first-page":"53","DOI":"10.3390\/pharmaceutics3010053","volume":"3","author":"E Fernandez","year":"2011","unstructured":"Fernandez E, Perez R, Hernandez A, Tejada P, Arteta M, Ramos JT. Factors and mechanisms for pharmacokinetic differences between pediatric population and adults. Pharmaceutics. 2011;3:53\u201372. https:\/\/doi.org\/10.3390\/pharmaceutics3010053.","journal-title":"Pharmaceutics"},{"key":"1672_CR32","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1056\/NEJMra035092","volume":"349","author":"GL Kearns","year":"2003","unstructured":"Kearns GL, Abdel-Rahman SM, Alander SW, Blowey DL, Leeder JS, Kauffman RE. Developmental pharmacology \u2014 drug disposition, action, and therapy in infants and children. N Engl J Med. 2003;349:1157\u201367. https:\/\/doi.org\/10.1056\/NEJMra035092.","journal-title":"N Engl J Med"},{"key":"1672_CR33","doi-asserted-by":"publisher","first-page":"601","DOI":"10.2174\/138920011796504527","volume":"12","author":"S Shi","year":"2011","unstructured":"Shi S, Klotz U. Age-related changes in pharmacokinetics. Curr Drug Metab. 2011;12:601\u201310. https:\/\/doi.org\/10.2174\/138920011796504527.","journal-title":"Curr Drug Metab"},{"key":"1672_CR34","doi-asserted-by":"publisher","DOI":"10.3390\/CANCERS13040798","volume":"13","author":"M Suttorp","year":"2021","unstructured":"Suttorp M, Millot F, Sembill S, Deutsch H, Metzler M. Definition, epidemiology, pathophysiology, and essential criteria for diagnosis of pediatric chronic myeloid leukemia. Cancers (Basel). 2021;13:798. https:\/\/doi.org\/10.3390\/CANCERS13040798.","journal-title":"Cancers (Basel)"},{"key":"1672_CR35","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1046\/j.1460-9592.1998.00744.x","volume":"8","author":"F Reinoso\u2010Barbero","year":"1998","unstructured":"Reinoso\u2010Barbero F, Calvo C, Ruza F, L\u00f3pez-Herce J, Bueno M, Garc\u00eda S. Reference values of gastric intramucosal pH in children. Paediatr Anaesth. 1998;8:135\u20138. https:\/\/doi.org\/10.1046\/j.1460-9592.1998.00744.x.","journal-title":"Paediatr Anaesth"}],"container-title":["Clinical Pharmacokinetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40262-026-01672-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40262-026-01672-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,4]],"date-time":"2026-09-04T16:23:15Z","timestamp":1788538995000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40262-026-01672-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,27]]},"references-count":35,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["1672"],"URL":"https:\/\/doi.org\/10.1007\/s40262-026-01672-y","relation":{},"ISSN":["0312-5963","1179-1926"],"issn-type":[{"value":"0312-5963","type":"print"},{"value":"1179-1926","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,27]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 June 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 July 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Alwin D.R. Huitema is an Editorial Board member of\n                      Clinical Pharmacokinetics\n                      . Alwin D.R. Huitema was not involved in the selection of peer reviewers for the manuscript nor any of the subsequent editorial decisions. Andrew Bukowinski reports no conflicts of interest. Matthew Kutny reports institutional research grant funding from\u00a0Astellas Pharma, Celgene Corporation, Cellectis, Incyte Corporation, Jazz Pharmaceuticals, Novartis Pharmaceuticals, Syndax Pharmaceuticals, and SUTRO Biopharma. C. Michel Zwaan reports serving as a consultant\/advisory board member for Incyte, Takeda, Johnson&Johnson, Sanofi, Syndax, Bristol Meyers Squibb, Roche, Kura Oncology Inc., Novartis, Pfizer, Abbvie, Daiichi Sankyo, Servier, Astra Zeneca. Received institutional funding from Pfizer, Daiichi Sankyo, Takeda, Abbvie, Jazz pharma, and Kura Oncology. Karey Kowalski is an employee of and owns stock in Pfizer Inc. Brian Jermain is an employee of and owns stock in Pfizer Inc. May Garrett is an employee of and owns stock in Pfizer Inc.","order":1,"name":"Ethics","label":"Conflict of Interest","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Anonymized data are available in consultation with the sponsor and subject to review.","order":2,"name":"Ethics","label":"Data Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Code for analyses are available in consultation with the sponsor and subject to review.","order":3,"name":"Ethics","label":"Code Availability","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards.","order":4,"name":"Ethics","label":"Ethical Approval","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Written informed consent was obtained from each participant before conducting any study procedures.","order":5,"name":"Ethics","label":"Consent to Participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Consent was obtained from participants in this trial.","order":6,"name":"Ethics","label":"Consent for Publication","group":{"name":"EthicsHeading","label":"Declarations"}}]}}